EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antibiotic disruption of the gut microbiome triggers IBD-like proteolytic activity

Lael Werner, Tal Nissenbaum-Toren, Morine Fibelman, Haim Leibovitzh, Nathaniel Aviv Cohen, Moran Brenner, Lior Lobel, Nitsan Maharshak

Cell Reports · 2026

DOI: 10.1016/j.celrep.2026.117478 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2026. Verfasst von Lael Werner und 7 weiteren Autor:innen. Beteiligte Einrichtung: Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel; Department of Gastroenterology and Liver Diseases, Tel Aviv Medic…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Proteolysis, Gastrointestinal Microbiome, Inflammatory Bowel Diseases. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Leona M and Harry B Helmsley Charitable Trust, Israel Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibiotics (Abx) are essential in medicine but can disrupt gut microbiota, potentially contributing to inflammatory bowel diseases (IBDs). This study employed fecal metagenomics and metaproteomics to evaluate the effects of Abx in patients with pouchitis, ulcerative colitis (UC), and non-IBD controls. Each group displayed distinct microbiome profiles, with metaproteomes more affected by Abx than metagenomes. Proteomic analysis revealed increased pancreatic protease activity and fecal proteolytic activity in all groups, except in patients without IBD before Abx, consistent with impaired epithelial barrier integrity. Abx also decreased bacterial protease inhibitors, which may control proteolysis and help maintain gut balance. These findings emphasize the importance of understanding Abx-induced proteolytic shifts in IBD and highlight metaproteomics as a valuable tool for studying host-microbiome interactions. Future research should explore the molecular mechanisms that regulate bacterial protease inhibitor levels and their effects on intestinal health.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsProteolysisGastrointestinal MicrobiomeInflammatory Bowel DiseasesHumansPeptide HydrolasesProteomicsColitis, UlcerativeFecesPouchitis

Stichwörter der Autor:innen

CP: microbiologyantibioticsgut microbiomemetaproteomicspouchitisproteolytic activityulcerative colitis

Substanzen

Anti-Bacterial AgentsPeptide Hydrolases

Autor:innen und Institutionen

  • Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel; Department of Gastroenterology and Liver Diseases, Tel Aviv Medical Center, Tel Aviv, Israel.
  • The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel.
  • The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel. Electronic address: lior.lobel@biu.ac.il.
  • Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel; Department of Gastroenterology and Liver Diseases, Tel Aviv Medical Center, Tel Aviv, Israel. Electronic address: nitsanm@tlvmc.gov.il.

Förderung

  • The Leona M and Harry B Helmsley Charitable Trust
  • Israel Science Foundation

Zitieren

APA

Werner, L., Nissenbaum-Toren, T., Fibelman, M., Leibovitzh, H., Cohen, N. A., Brenner, M., Lobel, L., & Maharshak, N. (2026). Antibiotic disruption of the gut microbiome triggers IBD-like proteolytic activity. Cell Reports. https://doi.org/10.1016/j.celrep.2026.117478

Vancouver

Werner L, Nissenbaum-Toren T, Fibelman M, Leibovitzh H, Cohen NA, Brenner M, et al. Antibiotic disruption of the gut microbiome triggers IBD-like proteolytic activity. Cell Reports. 2026. doi:10.1016/j.celrep.2026.117478

BibTeX
@article{Werner2026,
  author = {Werner, Lael and Nissenbaum-Toren, Tal and Fibelman, Morine and Leibovitzh, Haim and Cohen, Nathaniel Aviv and Brenner, Moran and Lobel, Lior and Maharshak, Nitsan},
  title = {Antibiotic disruption of the gut microbiome triggers IBD-like proteolytic activity},
  journal = {Cell Reports},
  year = {2026},
  doi = {10.1016/j.celrep.2026.117478}
}
Kostenlos starten →